Anixa Biosciences (ANIX) Accumulated Expenses (2010 - 2026)

Anixa Biosciences (ANIX) has 17 years of Accumulated Expenses data on file, last reported at $1.2 million in Q2 2026.

• Quarterly Accumulated Expenses fell 23.05% year-over-year to $1.2 million in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $1.2 million (down 23.05% YoY) and the FY2025 annual result came in at $1.8 million, down 9.51% from the prior year.
• Accumulated Expenses eased to $1.2 million in Q2 2026, from $1.8 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $1.9 million in Q4 2024 to a low of $1.1 million in Q2 2022.
• A 5-year average of $1.5 million and a median of $1.4 million in 2024 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses jumped 57.63% — and 2026, when it retreated 23.05%.
• Tracing ANIX's Accumulated Expenses over 5 years: stood at $1.7 million in 2022, then rose by 2.55% to $1.8 million in 2023, then increased by 9.94% to $1.9 million in 2024, then retreated by 9.51% to $1.8 million in 2025, then tumbled by 31.57% to $1.2 million in 2026.
• The last three Accumulated Expenses figures came in at $1.2 million (Q2 2026), $1.8 million (Q4 2025), and $1.8 million (Q3 2025), per Business Quant data.